ConductScience.org, home

Paper21189395

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.

Press MF and 19 others. J Clin Oncol, 2011. Cited by 172 papers, by iCite.

Cite this record

ConductScience Library. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. Papers, record 21189395. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21189395

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.
PubMed
Journal
J Clin Oncol
PubMed
Year
2011
PubMed
Publication types
Clinical Trial, Phase III, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.
PubMed
Citations, by iCite
172
iCite
Relative citation ratio, by iCite
4.5
iCite
Revised in PubMed
2024-04-16
PubMed

Authors20

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Press MFMichael F
2Sauter GGuido
3Buyse MMarc
4Bernstein LLeslie
5Guzman RRoberta
6Santiago AAngela
7Villalobos IEIvonne E
8Eiermann WWolfgang
9Pienkowski TTadeusz
10Martin MMiguel
11Robert NNicholas
12Crown JJohn
13Bee VValerie
14Taupin HHenry
15Flom KJKerry J
16Tabah-Fisch IIsabelle
17Pauletti GGiovanni
18Lindsay MAMary-Ann
19Riva AAlessandro
20Slamon DJDennis J

Source PubMed

Download CSV of authors

Topics24

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AnthracyclinesMajor topic
Antigens, NeoplasmMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Breast NeoplasmsMajor topic
DNA Topoisomerases, Type IIMajor topic
DNA-Binding ProteinsMajor topic
Gene AmplificationMajor topic
Genes, erbB-2Major topic
Adult
Aged
Disease-Free Survival
Female
Gene Expression Regulation, Neoplastic
Genetic Predisposition to Disease
Humans
In Situ Hybridization, Fluorescence
Middle Aged
Poly-ADP-Ribose Binding Proteins
Prognosis
Proportional Hazards Models
Risk Assessment
Statistics, Nonparametric
Survival Analysis
Treatment Outcome

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 CA048780NCI NIH HHSUnited StatesR01CA048780PubMed and NIHNIH RePORTER
R01 CA077398NCI NIH HHSUnited StatesR01CA077398PubMed and NIHNIH RePORTER
CA48780NCI NIH HHSUnited StatesR01CA048780PubMed and NIHNIH RePORTER
CA77398NCI NIH HHSUnited StatesR01CA077398PubMed and NIHNIH RePORTER

Download CSV of grants

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT00021255Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast CancerBackgroundClinicalTrials.gov
NCT04403984Investigation of Genomic Alteration in Patients With Luminal A or Luminal B SubtypesBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in21670460Does topoisomerase II-alpha gene amplification provide useful information for treatment selection in patients with breast carcinoma?https://conductscience.org/library/papers/21670460

Source PubMed

Download CSV of comments and corrections

References62

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120079691Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).Lancet Oncol2010https://conductscience.org/library/papers/20079691PubMed
216234514
retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
J Clin Oncol2005https://conductscience.org/library/papers/16234514PubMed
311121461HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15.J Natl Cancer Inst2000https://conductscience.org/library/papers/11121461PubMed
416258081Trastuzumab cardiac side effects: only time will tell.J Clin Oncol2005https://conductscience.org/library/papers/16258081PubMed
520038724HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients.J Clin Oncol2010https://conductscience.org/library/papers/20038724PubMed
615994142
Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
J Clin Oncol2005https://conductscience.org/library/papers/15994142PubMed
714632727Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer--more common than anticipated.Cytopathology2003https://conductscience.org/library/papers/14632727PubMed
89747867erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.J Natl Cancer Inst1998https://conductscience.org/library/papers/9747867PubMed
912755489HER-2/neu and topoisomerase IIalpha in breast cancer.Breast Cancer Res Treat2003https://conductscience.org/library/papers/12755489PubMed
1016137437
HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results.
Clin Breast Cancer2005https://conductscience.org/library/papers/16137437PubMed
1112560435HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer.J Clin Oncol2003https://conductscience.org/library/papers/12560435PubMed
1212118023Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.J Clin Oncol2002https://conductscience.org/library/papers/12118023PubMed
1317284714Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.J Natl Cancer Inst2007https://conductscience.org/library/papers/17284714PubMed
1412602919Comparison of topoisomerase-IIalpha gene status between primary breast cancer and corresponding distant metastatic sites.Breast Cancer Res Treat2003https://conductscience.org/library/papers/12602919PubMed
1518465341The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D.Acta Oncol2008https://conductscience.org/library/papers/18465341PubMed
163299059Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene.Mol Cell Biol1987https://conductscience.org/library/papers/3299059PubMed
1716166438Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.Clin Cancer Res2005https://conductscience.org/library/papers/16166438PubMed
1818768436Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.J Clin Oncol2008https://conductscience.org/library/papers/18768436PubMed
1916258083
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
J Clin Oncol2005https://conductscience.org/library/papers/16258083PubMed
207779724CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study).Br J Cancer1995https://conductscience.org/library/papers/7779724PubMed

See all 62 referencesDownload CSV of references

Cited by95

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 172 citations.

PMIDTitleJournalYearIn PapersSource
42941759TOP2A Overexpression as a Prognostic Biomarker in High-Grade Meningioma: An Integrated Single-Cell and Bulk Transcriptomic Study.Int J Mol Sci2026https://conductscience.org/library/papers/42941759PubMed
42465750Targeting the E2F6-TOP2A-DKK1 axis: a novel therapeutic strategy for EMT-driven hepatocellular carcinoma progression.Front Immunol2026https://conductscience.org/library/papers/42465750PubMed
42106529Identification of biomarkers associated with diagnosis of gastroesophageal junction adenocarcinoma and their correlation with immune infiltration.Discov Oncol2026https://conductscience.org/library/papers/42106529PubMed
42098228Expression of HER2 in the eye and the potential for on-target side effects with antibody-drug conjugates.Sci Rep2026https://conductscience.org/library/papers/42098228PubMed
41648744Integration of genomic aberrations to predict clinical outcomes for patients with gastroesophageal adenocarcinoma receiving neoadjuvant chemotherapy.ESMO Gastrointest Oncol2024https://conductscience.org/library/papers/41648744PubMed
41153808Novel Cross-Cancer Hub Genes in Doxorubicin Resistance Identified by Transcriptional Mapping.Biomedicines2025https://conductscience.org/library/papers/41153808PubMed
40831931A four-gene signature identified by integrated transcriptomic analysis for differential diagnosis and prognosis of uterine smooth muscle tumors.Front Oncol2025https://conductscience.org/library/papers/40831931PubMed
40123578Targeting DNA Topoisomerase IIα in Retinoblastoma: Implications in EMT and Therapeutic Strategies.Biologics2025https://conductscience.org/library/papers/40123578PubMed
39670307Advances in research on malignant tumors and targeted agents for TOP2A (Review).Mol Med Rep2025https://conductscience.org/library/papers/39670307PubMed
39063165Bicalutamide Enhances Conventional Chemotherapy in In Vitro and In Vivo Assays Using Human and Canine Inflammatory Mammary Cancer Cell Lines.Int J Mol Sci2024https://conductscience.org/library/papers/39063165PubMed
38453781
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.
Breast Cancer Res Treat2024https://conductscience.org/library/papers/38453781PubMed
37746544Evaluation of Expression Level of miR-3135b-5p in Blood Samples of Breast Cancer Patients Experiencing Chemotherapy-Induced Cardiotoxicity.Indian J Clin Biochem2023https://conductscience.org/library/papers/37746544PubMed
37176164Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase Inhibitors.Int J Mol Sci2023https://conductscience.org/library/papers/37176164PubMed
36698078A clinicopathological study and survival analysis of 99 breast cancers with HER2/CEP17 ratio ≥ 2.0 and an average HER2 copy number < 4.0 per cell in China.BMC Cancer2023https://conductscience.org/library/papers/36698078PubMed
36551262Comprehensive Analysis of Transcriptomics and Genetic Alterations Identifies Potential Mechanisms Underlying Anthracycline Therapy Resistance in Breast Cancer.Biomolecules2022https://conductscience.org/library/papers/36551262PubMed
36428728
Association between CD8+ Tumor Infiltrating Lymphocytes and the Clinical Outcome of Patients with Operable Breast Cancer Treated with Adjuvant Dose-Dense Chemotherapy-A 10 Year Follow-Up Report of a Hellenic Cooperative Oncology Group Observational Study.
Cancers (Basel)2022https://conductscience.org/library/papers/36428728PubMed
36358657A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix® PC1 System.Cancers (Basel)2022https://conductscience.org/library/papers/36358657PubMed
35805084Mitochondria and Doxorubicin-Induced Cardiomyopathy: A Complex Interplay.Cells2022https://conductscience.org/library/papers/35805084PubMed
35792986Genomic copy number alterations as biomarkers for triple negative pregnancy-associated breast cancer.Cell Oncol (Dordr)2022https://conductscience.org/library/papers/35792986PubMed
35565244Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals.Cancers (Basel)2022https://conductscience.org/library/papers/35565244PubMed

See all 95 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
TOP2A7153PubTator's text mininghttps://conductscience.org/library/genes/7153NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/21189395

GET https://conductscience.org/api/papers/v1/21189395/references?page=2